164 related articles for article (PubMed ID: 26731315)
21. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Tewari KS; Eskander RN; Monk BJ
Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
[TBL] [Abstract][Full Text] [Related]
22. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.
Karve TM; Preet A; Sneed R; Salamanca C; Li X; Xu J; Kumar D; Rosen EM; Saha T
PLoS One; 2012; 7(6):e37697. PubMed ID: 22685544
[TBL] [Abstract][Full Text] [Related]
24. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
Zhao D; Zhang W; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
[TBL] [Abstract][Full Text] [Related]
25. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
Kim MK; James J; Annunziata CM
BMC Cancer; 2015 Mar; 15():196. PubMed ID: 25884494
[TBL] [Abstract][Full Text] [Related]
26. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M
Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723
[TBL] [Abstract][Full Text] [Related]
27. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
28. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
29. Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer.
Labanca E; De Luca P; Gueron G; Paez A; Moiola CP; Massillo C; Porretti J; Giudice J; Zalazar F; Navone N; Vazquez E; De Siervi A
Mol Cancer Res; 2015 Nov; 13(11):1455-64. PubMed ID: 26227317
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer susceptibility gene 1 regulates oxidative damage via nuclear factor erythroid 2-related factor 2 in oral cancer cells.
Yu X; Liu Y; Pan K; Sun P; Li J; Li L; Chen Q; Sun Z
Arch Oral Biol; 2022 Jul; 139():105447. PubMed ID: 35512617
[TBL] [Abstract][Full Text] [Related]
31. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.
Chen MC; Zhou B; Zhang K; Yuan YC; Un F; Hu S; Chou CM; Chen CH; Wu J; Wang Y; Liu X; Smith DL; Li H; Liu Z; Warden CD; Su L; Malkas LH; Chung YM; Hu MC; Yen Y
Mol Pharmacol; 2015 Jun; 87(6):996-1005. PubMed ID: 25814515
[TBL] [Abstract][Full Text] [Related]
32. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Chiyoda T; Hart PC; Eckert MA; McGregor SM; Lastra RR; Hamamoto R; Nakamura Y; Yamada SD; Olopade OI; Lengyel E; Romero IL
Cancer Prev Res (Phila); 2017 Apr; 10(4):255-266. PubMed ID: 28264838
[TBL] [Abstract][Full Text] [Related]
33. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways.
Ouyang G; Yao L; Ruan K; Song G; Mao Y; Bao S
Cell Biol Int; 2009 Dec; 33(12):1237-44. PubMed ID: 19732843
[TBL] [Abstract][Full Text] [Related]
34. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
36. Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells.
Kang HJ; Hong YB; Kim HJ; Wang A; Bae I
Toxicol Lett; 2012 Mar; 209(2):154-60. PubMed ID: 22192953
[TBL] [Abstract][Full Text] [Related]
37. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Kanakkanthara A; Kurmi K; Ekstrom TL; Hou X; Purfeerst ER; Heinzen EP; Correia C; Huntoon CJ; O'Brien D; Wahner Hendrickson AE; Dowdy SC; Li H; Oberg AL; Hitosugi T; Kaufmann SH; Weroha SJ; Karnitz LM
Cancer Res; 2019 Dec; 79(23):5920-5929. PubMed ID: 31619387
[TBL] [Abstract][Full Text] [Related]
39. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
Zhong A; Zhang H; Xie S; Deng M; Zheng H; Wang Y; Chen M; Lu R; Guo L
Oncol Rep; 2018 Apr; 39(4):1747-1756. PubMed ID: 29393493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
